IKKβ inhibitor identification: a multi-filter driven novel scaffold
暂无分享,去创建一个
Shanthi Nagarajan | Hyunah Choo | Yong Seo Cho | Kye Jung Shin | Kwang-Seok Oh | Byung Lee | Ae Nim Pae | H. Choo | Y. Cho | A. Pae | B. Lee | K. Shin | S. Nagarajan | K. Oh | Hyunah Choo
[1] J. R. Landis,et al. The measurement of observer agreement for categorical data. , 1977, Biometrics.
[2] D B Young,et al. IKK-1 and IKK-2: cytokine-activated IkappaB kinases essential for NF-kappaB activation. , 1997, Science.
[3] G. Keserű,et al. Functional virtual screening of estrogen receptor α modulators by FlexX-Pharm , 2005 .
[4] J. Adams,et al. Novel IKK inhibitors: β-carbolines , 2003 .
[5] R. Hersperger,et al. Design and preparation of 2-benzamido-pyrimidines as inhibitors of IKK. , 2006, Bioorganic & medicinal chemistry letters.
[6] Stuart Paine,et al. Hit-to-lead studies: the discovery of potent, orally active, thiophenecarboxamide IKK-2 inhibitors. , 2004, Bioorganic & medicinal chemistry letters.
[7] Shanthi Nagarajan,et al. IKKbeta inhibitors identification part I: homology model assisted structure based virtual screening. , 2009, Bioorganic & medicinal chemistry.
[8] G. De’ath,et al. CLASSIFICATION AND REGRESSION TREES: A POWERFUL YET SIMPLE TECHNIQUE FOR ECOLOGICAL DATA ANALYSIS , 2000 .
[9] Jaina Mistry,et al. A rapid computational filter for cytochrome P450 1A2 inhibition potential of compound libraries. , 2005, Journal of medicinal chemistry.
[10] C. Homon,et al. Evolution of the Thienopyridine Class of Inhibitors of IκB Kinase-β: Part I: Hit-to-Lead Strategies , 2006 .
[11] T. Yoshino,et al. Synthesis and structure-activity relationships of novel IKK-beta inhibitors. Part 2: Improvement of in vitro activity. , 2004, Bioorganic & medicinal chemistry letters.
[12] P. Bamborough,et al. The discovery of 2 -amino -3,5 -diarylbenzamide inhibitors of IKK-α and IKK-β kinases , 2007 .
[13] Toby Lawrence,et al. IKKalpha limits macrophage NF-kappaB activation and contributes to the resolution of inflammation. , 2005, Nature.
[14] N. Munshi,et al. NF-κB as a Therapeutic Target in Multiple Myeloma* , 2002, The Journal of Biological Chemistry.
[15] Arup K. Ghose,et al. Knowledge Based Prediction of Ligand Binding Modes and Rational Inhibitor Design for Kinase Drug Discovery , 2008 .
[16] Daniel P Vercauteren,et al. Recursive partitioning for the prediction of cytochromes P450 2D6 and 1A2 inhibition: importance of the quality of the dataset. , 2006, Journal of medicinal chemistry.
[17] Thomas Lengauer,et al. Flexible docking under pharmacophore type constraints , 2002, J. Comput. Aided Mol. Des..
[18] Jeffrey Jie-Lou Liao,et al. Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors. , 2007, Journal of medicinal chemistry.
[19] K. McIntyre,et al. Synthesis and structure–activity relationship of imidazo(1,2-a)thieno(3,2-e)pyrazines as IKK-β inhibitors , 2007 .
[20] Toby Lawrence,et al. IKKα limits macrophage NF-κB activation and contributes to the resolution of inflammation , 2005, Nature.
[21] H. Choo,et al. 3D QSAR pharmacophore model based on diverse IKKβ inhibitors , 2011, Journal of molecular modeling.
[22] A. Baldwin,et al. The I kappa B proteins: multifunctional regulators of Rel/NF-kappa B transcription factors. , 1993, Genes & development.
[23] H. Choo,et al. IKKbeta inhibitors identification part II: ligand and structure-based virtual screening. , 2010, Bioorganic & medicinal chemistry.
[24] Matthias Mann,et al. IKK-1 and IKK-2: Cytokine-Activated IκB Kinases Essential for NF-κB Activation , 1997 .
[25] J. Strnad,et al. IκB kinase inhibitors for treating autoimmune and inflammatory disorders: potential and challenges , 2007 .
[26] Christopher Lowe,et al. A novel series of potent and selective IKK2 inhibitors. , 2004, Bioorganic & medicinal chemistry letters.
[27] K. Ziegelbauer,et al. Synthesis and structure–activity relationships of novel IKK-β inhibitors. Part 3: Orally active anti-inflammatory agents , 2004 .
[28] Margaret R. Karagas,et al. Model-based clustering of DNA methylation array data: a recursive-partitioning algorithm for high-dimensional data arising as a mixture of beta distributions , 2008, BMC Bioinformatics.
[29] Tímea Polgár,et al. Virtual screening for beta-secretase (BACE1) inhibitors reveals the importance of protonation states at Asp32 and Asp228. , 2005, Journal of medicinal chemistry.
[30] Inhibition of IKK-2 by 2-[(aminocarbonyl)amino]-5-acetylenyl-3-thiophenecarboxamides. , 2005, Bioorganic & medicinal chemistry letters.
[31] G. Keserű,et al. Comparative virtual and experimental high-throughput screening for glycogen synthase kinase-3beta inhibitors. , 2005, Journal of medicinal chemistry.
[32] Arup K. Ghose,et al. Knowledge based prediction of ligand binding modes and rational inhibitor design for kinase drug discovery. , 2008, Journal of medicinal chemistry.
[33] J. Adams,et al. Novel IKK inhibitors: beta-carbolines. , 2003, Bioorganic & Medicinal Chemistry Letters.
[34] BMC Bioinformatics , 2005 .
[35] K. McIntyre,et al. Synthesis and biological evaluation of 4-amino derivatives of benzimidazoquinoxaline, benzimidazoquinoline, and benzopyrazoloquinazoline as potent IKK inhibitors. , 2007, Bioorganic & medicinal chemistry letters.
[36] H. Oki,et al. Synthesis and Structure Activity Relationship Studies of Benzothieno[3,2- b ]furan Derivatives as a Novel Class of IKKβ Inhibitors , 2007 .
[37] Liang-Tsung Huang,et al. iPTREE-STAB: interpretable decision tree based method for predicting protein stability changes upon mutations , 2007, Bioinform..
[38] György M. Keserü,et al. Impact of Ligand Protonation on Virtual Screening against β-Secretase (BACE1) , 2007, J. Chem. Inf. Model..
[39] N. Munshi,et al. NF-kappa B as a therapeutic target in multiple myeloma. , 2002, The Journal of biological chemistry.
[40] Marta Bellini,et al. Straightforward recursive partitioning model for discarding insoluble compounds in the drug discovery process. , 2008, Journal of medicinal chemistry.
[41] Evolution of the thienopyridine class of inhibitors of IkappaB kinase-beta: part I: hit-to-lead strategies. , 2006, Journal of medicinal chemistry.
[42] K. McIntyre,et al. Synthesis and structure-activity relationship of imidazo(1,2-a)thieno(3,2-e)pyrazines as IKK-beta inhibitors. , 2007, Bioorganic & Medicinal Chemistry Letters.
[43] P. Bamborough,et al. The discovery of 2-amino-3,5-diarylbenzamide inhibitors of IKK-alpha and IKK-beta kinases. , 2007, Bioorganic & medicinal chemistry letters.
[44] T. Maniatis,et al. Signal-induced degradation of I kappa B alpha requires site-specific ubiquitination. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[45] M. Murcko,et al. Kinase-likeness and kinase-privileged fragments: toward virtual polypharmacology. , 2008, Journal of medicinal chemistry.